During the last session, Humacyte Inc (NASDAQ:HUMA)’s traded shares were 5.88 million, with the beta value of the company hitting 1.53. At the end of the trading day, the stock’s price was $2.01, reflecting an intraday gain of 0.50% or $0.01. The 52-week high for the HUMA share is $9.97, that puts it down -396.02 from that peak though still a striking 2.49% gain since the share price plummeted to a 52-week low of $1.96. The company’s market capitalization is $258.62M, and the average intraday trading volume over the past 10 days was 5.02 million shares, and the average trade volume was 2.87 million shares over the past three months.
Humacyte Inc (HUMA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. HUMA has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.25.
Humacyte Inc (NASDAQ:HUMA) trade information
Humacyte Inc (HUMA) registered a 0.50% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.50% in intraday trading to $2.01, hitting a weekly high. The stock’s 5-day price performance is -36.79%, and it has moved by -41.40% in 30 days. Based on these gigs, the overall price performance for the year is -35.99%. The short interest in Humacyte Inc (NASDAQ:HUMA) is 26.6 million shares and it means that shorts have 11.69 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 74.88% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $10 respectively. As a result, HUMA is trading at a discount of -397.51% off the target high and -198.51% off the low.
Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 640.2k by the end of current fiscal year.
While earnings are projected to return -27.29% in 2025, the next five years will return 46.92% per annum.
HUMA Dividends
Humacyte Inc is due to release its next quarterly earnings on 2025-Mar-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Humacyte Inc insiders own 26.87% of total outstanding shares while institutional holders control 35.02%, with the float percentage being 47.89%. BLACKROCK INC. is the largest shareholder of the company, while 211.0 institutions own stock in it. As of 2024-06-30, the company held over 7.14 million shares (or 5.9912% of all shares), a total value of $34.27 million in shares.
The next largest institutional holding, with 4.73 million shares, is of VANGUARD GROUP INC’s that is approximately 4.3693% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.7 million.
Also, the Mutual Funds coming in first place with the largest holdings of Humacyte Inc (HUMA) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 2.59 shares. This amounts to just over 2.06 percent of the company’s overall shares, with a $5.21 million market value. The same data shows that the other fund manager holds slightly less at 2.45, or about 1.95% of the stock, which is worth about $4.93 million.
